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Abstract
Impaired mineral homeostasis and inflammation are hallmarks of chronic kidney disease
(CKD), yet the underlying mechanisms of electrolyte regulation during CKD are still unclear.
Here, we applied two different murine models, partial nephrectomy and adenine-enriched
dietary intervention, to induce kidney failure and to investigate the subsequent impact on
systemic and local renal factors involved in Ca2+ and Pi regulation. Our results demon-
strated that both experimental models induce features of CKD, as reflected by uremia, and
elevated renal neutrophil gelatinase-associated lipocalin (NGAL) expression. In our model
kidney failure was associated with polyuria, hypercalcemia and elevated urinary Ca2+
excretion. In accordance, CKD augmented systemic PTH and affected the FGF23-αklotho-
vitamin-D axis by elevating circulatory FGF23 levels and reducing renal αklotho expression.
Interestingly, renal FGF23 expression was also induced by inflammatory stimuli directly.
Renal expression of Cyp27b1, but not Cyp24a1, and blood levels of 1,25-dihydroxy vitamin
D3 were significantly elevated in both models. Furthermore, kidney failure was character-
ized by enhanced renal expression of the transient receptor potential cation channel sub-
family V member 5 (TRPV5), calbindin-D28k, and sodium-dependent Pi transporter type 2b
(NaPi2b), whereas the renal expression of sodium-dependent Pi transporter type 2a
(NaPi2a) and type 3 (PIT2) were reduced. Together, our data indicates two different models
of experimental kidney failure comparably associate with disturbed FGF23-αklotho-vitamin-
D signalling and a deregulated electrolyte homeostasis. Moreover, this study identifies local
tubular, possibly inflammation- or PTH- and/or FGF23-associated, adaptive mechanisms,
impacting on Ca2+/Pi homeostasis, hence enabling new opportunities to target electrolyte
disturbances that emerge as a consequence of CKD development.
PLOS ONE | DOI:10.1371/journal.pone.0142510 November 13, 2015 1 / 21
OPEN ACCESS
Citation: Pulskens WP, Verkaik M, Sheedfar F, van
Loon EP, van de Sluis B, Vervloet MG, et al. (2015)
Deregulated Renal Calcium and Phosphate Transport
during Experimental Kidney Failure. PLoS ONE 10
(11): e0142510. doi:10.1371/journal.pone.0142510
Editor: Jaap A. Joles, University Medical Center
Utrecht, NETHERLANDS
Received: April 15, 2015
Accepted: October 22, 2015
Published: November 13, 2015
Copyright: © 2015 Pulskens et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data is
included in the manuscript or given in the supporting
information.
Funding: This project is part of the NIGRAM
consortium, financially supported by the Dutch Kidney
Foundation (CP10.11). WPP,MV,EPL,FS,MGV,JGH
and RJB are authors who received the funding. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Chronic kidney disease (CKD) is a major public health issue with a high prevalence currently
affecting millions of people worldwide [1]. CKD results in a significant morbidity and mortality
and highly associates with the development of cardiovascular events, the primary cause of
death in CKD patients [2–4]. A prominent hallmark of CKD that may contribute to this
increased risk is a disturbed electrolyte homeostasis, including calcium (Ca2+) and phosphorus
(Pi) deregulation [5]. Physiological Ca
2+ and Pi levels in the blood are maintained by complex
endocrine systems comprising the parathyroid hormone (PTH) and phosphaturic hormone
Fibroblast Growth Factor 23 (FGF23) and vitamin D system [6–8]. PTH and FGF23 inhibit
renal Pi reabsorption and are the primary regulators of renal 1,25-dihydroxy vitamin D3 (active
vitamin-D) synthesis. 1,25-dihydroxy vitamin D3 itself also regulates urinary calcium excretion
by the kidney [6–8].
In addition to bone-derived FGF23, other cell types may contribute to circulating FGF23
levels, including fibroblasts and smooth muscle cells [9]. Moreover, several neuroendocrinolo-
gic factors and cytokines directly influence FGF23 secretion into the circulatory system [10,
11]. To enable downstream signalling, FGF23 requires membrane-bound αklotho as its obli-
gate co-receptor [12, 13]. αklotho is predominantly expressed in renal epithelium and the para-
thyroid gland, hence providing tissue-specificity for FGF23 signalling [14]. In addition, soluble
αklotho present in the circulation or urine can regulate electrolyte transport, through the epi-
thelial Ca2+ channel (TRPV5) [15] and the renal outer medullary potassium channel
(ROMK1) [16–19]. There are well-described reductions in renal and parathyroid klotho in
CKD. It has been shown [20] that CKD associates with reduced αklotho expression and that it
is related to elevated FGF23 levels, in response to persistent phosphate retention [21–23]. In
turn, this may lower systemic vitamin-D levels, which contributes to the pathogenesis of sec-
ondary hyperparathyroidism. The consequences of CKD-induced alterations in FGF23-
αklotho-vitamin-D signalling on renal tubular electrolyte regulatory mechanisms are, however,
still unclear. Hence, in the current study, we characterized the impact of two different experi-
mental models of progressive kidney failure on FGF23-αklotho-vitamin-D signalling and local
renal Ca2+ and Pi transport regulation. In addition we examined the consequences of inflam-
matory stimuli and the effect of FGF23 on several mineral-regulating channels on the tubular
epithelium.
Material and Methods
Ethical statement
This study was carried out in strict compliance with the legal Dutch animal welfare act. All
experimental procedures performed were approved by the animal ethics board of the Radboud
University Nijmegen (permit-no: RU-DEC 2013–068 and RU-DEC 2013–224) or by VU Uni-
versity Medical Center (VUmc), Amsterdam (permit-no: Fys 12–01) or by University Medical
Center Groningen (UMCG), Groningen (permit-no: 5321K and 6697C) and all efforts were
made to minimize suffering of the animals. A completed ARRIVE guidelines checklist is
included in S1 File.
Mice
Pathogen-free eight to ten weeks old male C57Bl/6 mice were purchased from Charles River
Laboratories and housed under standardized conditions in the animal facilities of the VU Uni-
versity Medical Center (VUmc), Amsterdam, Radboud University Medical Center, Nijmegen,
and University Medical Center Groningen (UMCG), Groningen, The Netherlands. Transgenic
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mice expressing enhanced green fluorescent protein (EGFP) driven by the TRPV5 promoter
(TRPV5-EGFP) were generated as described previously [24] and housed in the animal facility
of the Radboud University Medical Center [25]. The presence of EGFP expression was geneti-
cally confirmed by routine PCR screening. All mice received water and food ad libitum and
only age-matched male mice were used in this study. All experiments were approved and con-
ducted following the guidelines of the local Animal Ethical Committees, adhering the guide-
lines of the European animal welfare.
Partial (5/6) nephrectomy and urine collection
Prior to surgery a small volume of peripheral blood was collected into EDTA-coagulated
microtainers (BD Biosciences, Breda, The Netherlands). Partial nephrectomy (5/6Nx; n = 9)
was performed under standardized sterile conditions and induced as described before [26, 27].
Briefly, a small abdominal midline incision of the skin and muscles was made under general
anaesthesia (isoflurane) and preoperative analgesia (Buprenorphin; Temgesic (Schering-
Plough, Houten, The Netherlands), 0.05 mg/kg intramuscular). The left kidney was decapsu-
lated after which both, the upper and lower pole were ablated by cauterization (High-tempera-
ture fine tip Cautery, Bovie Medical Corporation, Clearwater, FL, USA). Subsequently, the
contralateral kidney was decapsulated and renal blood vessels and ureter were ligated, after
which the entire kidney was removed. The abdomen was closed with sutures in two layers and
all mice received subcutaneous injections of postoperative analgesia two days after surgery
(Ketoprofen; Ketofen (Merial S.A.S., Velserbroek, The Netherlands), 5 mg/kg). Sham-operated
mice were used as controls and underwent the similar protocol including decapsulation of both
kidneys, except for the renal ablation (n = 5). After three weeks, mice were placed into individ-
ual metabolic cages (Tecniplast, Buguggiate, Italy) enabling 24-hours urine collection. Mice
were sacrificed and blood was divided into EDTA- and heparin-coagulated microtainers and
centrifuged for 10 minutes (min) at 1,500 g at 4°C. Plasma samples were stored at -80°C. Rem-
nant renal tissue was isolated, subdivided into two equal parts and either directly snap-frozen
into liquid nitrogen or fixated in 1% w/v paraformaldehyde-lysine-periodate (PLP) solution for
2 hours (hrs) at room temperature, subsequently incubated overnight at 4°C in phosphate buff-
ered saline (PBS) containing 15% w/v sucrose before snap-frozen in liquid nitrogen.
Adenine-enriched dietary intervention
Prior to the start of diet, a small volume of peripheral blood was isolated by cheek puncture
into microvette tubes (Sarstedt, Etten-Leur, The Netherlands). Mice of about 25 gram body
weight were fed with a 0.2% w/w adenine (Sigma-Aldrich, Saint-Louis, MO, USA; cat.no.
A8626) containing diet (Bio Services; Uden, The Netherlands) during a period of either 2 or 4
weeks (n = 5/group). A control group (n = 5) was fed a standard diet and sacrificed after 4
weeks. Body weights were recorded every other day. After 2 or 4 weeks, mice were placed into
individual metabolic cages (Tecniplast) for 24 hrs before sacrificed under general anaesthesia
(isoflurane). Blood was isolated from the orbital sinus and collected in microvette tubes. Sam-
ples were allowed to clot for 2 hrs at room temperature and subsequently centrifuged 10 min at
9,000 g at 4°C to enable serum isolation, and subsequently stored at -80°C. Kidney tissue was
isolated and processed as described above.
Systemic administration of FGF23
Male TRPV5-EGFP mice of 5–7 weeks old received a single intravenous tail vein administra-
tion (IV) of 160 μg/kg Carrier-free recombinant mouse FGF23 (rFGF23; R&D Systems, Minne-
apolis, MN, USA; cat.no 2629-FG-CF) or vehicle (saline) in a total volume of 100 μl (n = 5/
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group). These mice were non-CKD mice and after 24 hrs were sacrificed under total anaesthe-
sia (isoflurane). Blood and kidney were collected and processed, as described above.
Systemic administration of Concanavalin A (ConA) and Tumor Necrosis
Factor (TNF)
Male mice received a single intravenous retro-orbital administration of 20 ug/kg of bodyweight
ConA or vehicle (PBS). A subset of mice received a single intravenous retro-orbital administra-
tion of 15 ug/kg of bodyweight TNF or vehicle. These mice were non-CKD mice and were sac-
rificed either after 8 hrs ConA administration or after 1 hr TNF administration. Kidney were
collected and processed as described above.
Electrolyte measurement
Systemic (using either EDTA-coagulated plasma from 5/6Nx mice or serum samples from
ADE-treated mice) and urinary concentrations of urea, and Pi were determined by in-hospital
services using automatic biochemical analyzers. Blood Ca2+ concentrations were determined in
heparin-coagulated plasma (from 5/6Nx mice) or serum (from ADE treated mice) and in uri-
nary samples, verified using a commercial serum standard (Precinorm U, Roche, Switzerland)
and measured as described previously [28].
Immunoassays
EDTA-coagulated plasma (from 5/6Nx mice) or serum (from ADE treated mice) samples were
used in enzyme-linked immunosorbent assays (ELISA) to determine circulating levels of FGF
23 and PTH 1–84 (both Immutopics International). Heparin-coagulated plasma (from 5/6Nx
mice) and serum (from ADE treated mice) samples were used to determine circulating
1,25-dihydroxy vitamin D3 (active vitamin-D) levels using a radioimmunoassay (Immunodiag-
nostic Systems; IDS, Liege, Belgium). All assays were performed according to the manufactur-
er’s protocols.
Western blotting
Renal tissues were homogenized in homogenization buffer A (HbA; 20 mM Tris-HCl (pH 7.4),
5 mMMgCl2, 5 mM NaH2PO4, 1 mM EDTA, 80 mM sucrose, 1 mM Phenylmethylsulfonyl
fluoride (PMSF), 1 μg/mL leupeptin, and 10 μg/mL pepstatin A). Total protein concentrations
were determined using the Bio-Rad Protein Assay (Bio-Rad, Munich, Germany) and protein
was solubilised by 30 min incubation at 37°C in Laemmli buffer with 0.1 M Dithiothreitol
(DTT). Protein (25 μg) was separated on an 8% w/v SDS-PAGE gel and transferred to a
PVDF-nitrocellulose membrane (Immobilon-P, Millipore Corporation, Bedford, MA). Blots
were blocked with 5% w/v non-fat dry milk (NFDM) into Tris-buffered saline (TBS)-0.1% v/v
Tween (TBS-T) and subsequently incubated overnight at 4°C with either anti αklotho
KL1-fragment (1:2,500; no. KM2076, kindly provided by prof. dr. M. Kuro-O, Texas, USA),
anti-GFP (1:5000; Sigma-Aldrich, Zwijndrecht, The Netherlands) or β-actin (1:10,000; Sigma,
clone AC-15) antibodies in 1% w/v NFDM/TBS-T. After incubation with appropriate perox-
yoxalate-conjugated secondary antibodies for 1 hr at room temperature, proteins were visual-
ized by chemiluminescence (Pierce, Rockford, IL). Immunoreactive proteins were scanned
using Chemidoc XRS (Bio-Rad, Veenendaal, The Netherlands) and intensities were analyzed
with Adobe Photoshop 7.0 software.
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RNA isolation and quantitative real-time RT-PCR
Total kidney mRNA was extracted from snap-frozen kidney tissue using Trizol Reagent (Life
Technologies; Bleiswijk, The Netherlands), according to the manufacturer’s guidelines. All
RNA samples were quantified by using an ND-1,000 spectrophotometer (NanoDrop Technol-
ogies, Rockland, DE). Total RNA (1.5 μg) was converted into cDNA using random hexamers
(Promega, Madison, WI, USA) and M-MLV reverse transcriptase (Life Technologies). Mouse
gene mRNA expression was analyzed by real-time quantitative reverse-transcription (RT)-
PCR performed on a Bio-Rad CFX96™ Real-Time qPCR or 7900HT system (Applied Biosys-
tems, Warrington, UK), using Bio-Rad iQ™ SYBR1 Green Supermix or Power SYBR Green
Master Mix (Roche, Mannheim, Germany). In addition specific gene expression was normal-
ized to housekeeping gene (hypoxanthine-guanine phosphoribosyl transferase; HPRT) and
analyzed according the 2^-ddCt method [29]. The mouse gene-specific primer sets used are
listed in S1 Table.
Immunohistochemistry
Immunohistochemical staining was performed on 5 μm cryosections of PLP-fixed renal tissue
samples [30]. Sections were stained with guinea pig anti-TRPV5 antibodies (1:2,000; [30]) or
mouse anti-calbindinD28k antibodies (1:2,000; Sigma Aldrich, Saint-Louis, MO, USA), with
concomitant tyramide signal amplification (TSA) enhancement (Perkin Elmer, Waltham, MA,
USA) following standard procedures. For visualization, sections were subsequently incubated
with appropriate Alexa-488-conjugated secondary antibodies (Sigma Aldrich). Fluorescent
images were made using a Zeiss fluorescence microscope (Sliedrecht, The Netherlands)
equipped with an AxioCam digital photo camera.
Statistics
Data are presented as mean ± SEM. Differences between groups were analyzed using Mann-
Whitney U tests and calculated using Graphpad Prism version 5.0 software. A p-value<0.05
was considered as statistically significant.
Results
Partial nephrectomy and adenine-enriched dietary treatment induced
kidney failure
The experimental models of partial nephrectomy (5/6Nx) and adenine-enriched dietary (ADE)
treatment both induced renal failure. This is reflected by elevated blood urea levels in 5/6Nx
mice compared to sham-operated mice after 3 weeks (Fig 1A) and the progressive uraemia
observed in ADE mice when compared to control mice (Fig 1B). In addition, renal mRNA
expression of tubular injury marker neutrophil gelatinase-associated lipocalin (NGAL) was
increased 12-fold in kidney tissue of 5/6Nx mice and>500-fold in ADE-treated mice (Fig 1C
and 1D). Moreover, mice subjected to either 5/6Nx or ADE treatment developed severe poly-
uria compared to sham-operated or control mice, respectively (Table 1).
Development of kidney failure disturbed electrolyte homeostasis
To investigate the consequences of induced renal failure on electrolyte homeostasis, blood lev-
els and urinary excretion of Ca2+ and Pi were determined. No variations in blood Ca
2+ and Pi
levels were found within experimental groups prior to onset of the experiments (data not
shown). 5/6Nx mice were hypercalcemic compared to sham-operated mice and additionally
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displayed elevated 24-hours urinary Ca2+ excretion (Table 2). In contrast, no differences were
observed in blood Pi levels or 24-hours urinary Pi excretion. In accordance, ADE-treated mice
displayed progressive hypercalcemia and increased urinary Ca2+ excretion when compared to
control mice (Table 2). Blood Pi levels progressively increased and were significantly elevated
after 4 weeks compared to control mice. No effects were detected on 24-hours urinary Pi excre-
tion, whereas after 4 weeks ADE diet the fractional excretion of Pi was significantly elevated
compared to control mice (26±2 and 40±3% Fractional Excretion of Pi) for control and ADE-
treated mice, respectively. In addition, blood Creatinine levels were significantly elevated in
both models while urine Creatinine levels were significantly reduced only in 5/6Nx mice
(Table 2).
Fig 1. Partial nephrectomy and adenine-enriched dietary treatment induced CKD.Mice subjected to (A) partial nephrectomy (5/6Nx; n = 9) after 3
weeks and (B) adenine-enriched dietary treatment (ADE; n = 5) for either 2 or 4 weeks display elevated blood urea levels, when compared to sham-operated
(n = 5) or control mice (n = 5), respectively. Renal expression of tubular injury marker NGAL is significantly elevated in (C) 5/6Nx mice and (D) ADEmice after
2 and 4 weeks, compared to sham-operated or control mice, respectively. Data are mean ± SEM. *: p<0.05 compared to either sham-operated or control
mice.
doi:10.1371/journal.pone.0142510.g001
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Induction of experimental CKD altered FGF23-αklotho signalling
In order to determine whether induced kidney failure results in altered FGF23-αklotho signal-
ling, we first measured blood FGF23 levels. FGF23 levels tended to be elevated in 5/6Nx mice
when compared to sham-operated mice (Fig 2A), and progressively increased in ADE mice
compared to control mice (Fig 2B; P<0.05). 5/6Nx did not affect renal mRNA expression of
the primary FGF23 receptor FGFR1, while αklotho expression tended to be decreased,
although not statistically significant (Fig 2C). ADE-treated mice demonstrated a mild raise in
FGFR1 (after 4 weeks) and a progressive (>2-fold) reduction in renal αklotho mRNA expres-
sion (Fig 2D; P<0.05 for both time points) when compared to control mice. In addition, a
2-fold decline in renal αklotho expression following ADE treatment was confirmed on protein
level (Fig 2E and 2F; P<0.05 for both time points).
Since inflammation is another hallmark of CKD we additionally checked whether an acute
inflammatory stimulus affects FGF23 levels directly. Interestingly, both ConA and TNF admin-
istration in vivo resulted in significantly elevated renal FGF23 mRNA expression in WTmice
(S1A Fig; P<0.05).
CKD progression augmented both renal vitamin-D synthesis and blood
PTH
CKD induced by either 5/6Nx or ADE-treatment augmented blood PTH levels in both 5/6Nx
(Fig 3A; P<0.05) and ADE-treated mice (Fig 3D; P<0.05 for both time points). CKD develop-
ment resulted in a 5- to 13-fold increased renal mRNA expression of the primary vitamin-D
Table 1. The effects of induced CKD on general physiological parameters.
Water intake (mL) Urine (mL) Food intake (gr) Faeces production (gr)
Sham (n = 5) 4.2±0.8 0.5±0.1 3.3±0.1 0.9±0.1
5/6Nx (n = 9) 8.4±1.0 * 2.5±0.2 * 3.2±0.3 0.9±0.1
Ctrl diet (n = 5) 4.4±0.3 1.3±0.2 3.9±0.1 2.0±0.1
ADE 2wk (n = 5) 10.8±0.5 * 6.0±0.2 * 3.8±0.1 1.7±0.1
ADE 4wk (n = 5) 11.1±0.4 * 7.9±0.4 * 3.4±0.1 * 1.4±0.1 *
Physiological measurements of mice subjected to 5/6Nx or sham operation, and subjected to ADE treatment for either 2 or 4 weeks or control diet. Data
are collected after 24 hours housing in individual metabolic cages, and are indicated as mean ± SEM.
*: p<0.05 compared to either sham-operation or to control diet.
doi:10.1371/journal.pone.0142510.t001
Table 2. The effects of induced CKD on deregulated Ca2+ and Pi homeostasis.
Creatinine (mmol/L) Ca2+ (mmol/L) Pi (mmol/L) Urinary Crea (mmol/L) Urinary Ca
2+ (μmol/24hr) Urinary Pi
(μmol/24hr)
Sham (n = 5) 21.6±1.2 1.7±0.1 1.7±0.0 1.9±0.2 2.0±0.3 28±2
5/6Nx (n = 9) 33.6±4.7 * 2.1±0.1 * 1.7±0.2 0.3±0.0 * 6.8±0.3 * 34±2
Ctrl diet (n = 5) 23.8±0.2 2.2±0.0 2.0±0.1 3.2±0.3 3.4±0.5 69±10
ADE2wk (n = 5) 27.2±1.2 * 2.4±0.1 2.1±0.1 3.2±0.4 9.3±0.7 * 83±13
ADE 4wk (n = 5) 53.6±0.9 * 2.8±0.0 * 2.7±0.2 * 3.8±0.1 18.7±1.2 * 58±8
Levels of creatinine, Ca2+ and Pi measured in blood or urine of sham-operated and 5/6Nx mice, or mice subjected to control diet or ADE treatment for
either 2 or 4 weeks. Data are indicated as mean ± SEM.
*: p<0.05 compared to either sham operation or to control diet.
doi:10.1371/journal.pone.0142510.t002
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Fig 2. Progression of CKD altered FGF23-αklotho signalling. Experimental CKD deregulates FGF23-αklotho signalling as reflected by (A) a tendency
towards elevated circulatory FGF23 levels in 5/6Nx mice and (B) progressively elevated FGF23 levels in ADE treated mice compared to control mice. Renal
mRNA expression of FGFR1 and αKlotho in (C) CKD induced 5/6Nx mice (black bars) compared with sham-operated groups (white bars) and in (D) 2 weeks
(black bars) and 4 weeks (gray bars) ADE treated mice compared with control groups (white bars). (E) Representative immunoblot (all 3 groups are done in
one blot) and (F) semi-quantitative analysis for αKlotho (E; upper panel) and β-actin (E; lower panel) protein expression in renal lysates of control or ADE
treated mice, which indicates reduced renal αKlotho protein expression upon CKD. Data are mean ± SEM. *: p<0.05 compared to control mice.
doi:10.1371/journal.pone.0142510.g002
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Fig 3. Experimental kidney failure augmented renal vitamin-D synthesis and induced secondary hyperparathyroidism. (A) PTH levels were elevated
three weeks after 5/6Nx. (B)mRNA expression of Cyp27b1 and Cyp24a1 in 5/6Nx mice (black bars) compared with sham-operated group (white bars). (C)
levels of 1,25-dihydroxy vitamin D3 in the blood were measured in mice with 5/6Nx nephrectomy. (D) PTH levels were elevated progressively in ADE treated
mice in both 2 weeks and 4 weeks ADE treated mice compared with control groups. (E)mRNA expression of Cyp27b1 and Cyp24a1 in CKD induced by 2
weeks (black bars) and 4 weeks (gray bars) ADE treated mice compared with control groups (white bars) and (F) levels of 1,25-dihydroxy vitamin D3
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regulatory enzyme 25-hydroxyvitaminD3 1α-hydroxylase (Cyp27b1) when compared to sham-
operated or control-diet fed mice, respectively (Fig 3B and 3E). In contrast, no effects were
observed on renal 1,25-dihydroxyvitamin D3 24-hydroxylase (Cyp24a1) mRNA expression. In
accordance, blood 1,25-dihydroxy vitamin D3 was higher in 5/6Nx mice compared to sham-
operated mice after 3 weeks (Fig 3C; p<0.05), and was as well elevated in elevated in 2 and 4
weeks ADE-treated mice compared to control mice (Fig 3F; P<0.05 for both time points). How-
ever 4 weeks ADE-treated mice exhibited a significant reduction in the level of 1,25-dihydroxy
vitamin D3 in compare to 2 weeks ADE-treated mice (Fig 3F; P<0.05; 4 weeks vs. 2 weeks).
CKD altered expression of crucial renal calcium and phosphate
transporters
To characterize the impact of CKD on tubular electrolyte transport regulation, the renal
expression of Ca2+ and Pi transporters was determined. Renal mRNA expression of TRPV5
and calbindin-D28k, which are specifically expressed in the distal convoluted tubule, was 2-fold
increased in 5/6Nx mice compared to sham-operated mice (Fig 4A). In line, microphotographs
of kidney tissue demonstrated concomitant increases on protein expression (Fig 4B). Addition-
ally, ADE treatment induced a 5-fold increase of renal TRPV5, but did not affect renal calbin-
din-D28k mRNA expression compared to control mice (Fig 4C). Comparable patterns were
also observed on protein level (Fig 4D).
Kidney injury induced by either 5/6Nx or ADE treatment reduced renal expression of
sodium-dependent Pi transporters NaPi2a and PIT2 more than 2-fold, but elevated renal NaPi2b
expression 2- to 20-fold compared to sham-operated or control mice, respectively (Fig 5A and
5B). On the contrary, renal expression of the thiazide-sensitive sodium-chloride co-transporter
(NCC) specifically present in the distal convoluted tubule, was not affected in either 5/6Nx or
ADE-treated mice (Data not shown).
FGF23 initiated adaptive mechanisms of renal calcium handling
To gain insight whether inflammatory stimuli directly affect renal Ca2+ handling, TRPV5
mRNA expression was determined in WTmice following ConA or TNF administration.
ConA, but not TNF administration resulted in elevated renal TRPV5 mRNA expression (S1B
Fig). Furthermore, to determine whether FGF23 affects renal Ca2+ handling, total kidney tissue
of transgenic mice, expressing EGFP driven by the TRPV5 promoter, was used to determine
mRNA expression of TRPV5, calbindin-D28k and EGFP, as a surrogate marker for TRPV5
transcription. Exogenous FGF23 administration resulted in an increased renal mRNA expres-
sion of TRPV5 (Fig 6A; P<0.05) and a tendency towards increased calbindin-D28k expression
(Fig 6A). In addition, EGFP mRNA expression tended to be elevated following FGF23 infusion,
although not statistically significant, when compared to control mice (Fig 6A).
TRPV5 protein expression cannot be determined by immunoblotting directly because of
the lack of appropriate primary antibodies. We therefore performed Western blotting on kid-
ney lysates from transgenic mice that expresses Enhanced Green Fluorescent Protein (EGFP 31
kD) driven by the TRPV5 promoter. Using this approach, determination of EGFP act as a sur-
rogate marker for TRPV5 expression. Representative pictures are shown in the Fig 6B. Digital
quantification analysis showed no significant differences in GFP protein expression level
between two groups (Fig 6C).
increased in 2 weeks ADE treated mice in compare to control mice. This was significantly reduced in 4 weeks ADE treated mice in compare to 2 weeks ADE
treated mice. Data are mean ± SEM. *: p<0.05 compared to either sham-operated or control mice.
doi:10.1371/journal.pone.0142510.g003
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Ca2+ levels in the blood were unaffected after 24 hrs following FGF23 administration (Fig
6D). Changes in systemic phosphate levels in comparison to the control group were not
detected. This might be due to the short-term period of the experiment. Unfortunately, we did
Fig 4. CKD development increased expression of tubular calcium transporters. (A)mRNA expression of the renal apical Ca2+ transporter TRPV5 and
intracellular calcium shuttling protein calbindin-D28K in the CKD induced 5/6Nx mice (black bars) compared to sham-operated mice (white bars). (B)
Representative microphotographs for renal TRPV5 and calbindin-D28K protein expression in kidney tissue from CKD induced 5/6Nx mice and sham-operated
mice. (C)mRNA expression of the renal apical Ca2+ transporter TRPV5 and intracellular calcium shuttling protein calbindin-D28K in mice fed with ADE diet for
2 weeks (black bars) and 4 weeks (gray bars) compared with control diet fed mice (white bars). (D) Representative microphotographs for renal TRPV5 and
calbindin-D28K protein expression in kidney tissue from CKD induced ADE treated (4 weeks) and control mice. Bars represent 100 μm. Data are
mean ± SEM. *: p<0.05 compared to either sham-operated or control mice.
doi:10.1371/journal.pone.0142510.g004
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not include the use of metabolic cages in the initial experimental setting. Therefore, the main
effect of FGF23 infusion (Pi excretion) cannot be validated completely. In order to determine
the local renal effects of rFGF23 infusion, gene expression of sodium-phosphate cotransporter
type 2 (NaPi2a and NaPi2b) in renal tissue were measured. No alterations between the groups
were however observed (Fig 6F).
Discussion
Ca2+ and Pi disturbances are a hallmark of CKD and an important risk factor for the develop-
ment of severe cardiovascular complications. In the current study, we characterized the impact
of CKD on systemic and local renal factors involved in Ca2+ and Pi regulation. Our data reveal
that two different experimental models of kidney failure induce comparable classical features
of CKD. A deregulated Ca2+ and Pi homeostasis and a significantly disturbed FGF23-αklotho-
vitamin-D axis were observed in both models. Both models resulted in an increased or
decreased expression of specific renal Ca2+ and Pi transporters, respectively.
First, both models of kidney failure, that is 5/6Nx and ADE treatment, induced clinical hall-
marks of CKD, as reflected by the development of uraemia and an elevated renal expression of
tubular injury marker NGAL. Our results are in accordance with previous studies demonstrat-
ing that both partial nephrectomy [31–33] and ADE treatment [34–36] closely resemble vari-
ous features of CKD development. The two models we used gave rise to different severity in
terms of its consequences on systemic urea and NGAL, electrolyte disturbances and alterations
of the FGF23-αklotho-vitamin-D axis, all pointing to more severe damage in the ADE-model.
Second, both experimental models disturbed Ca2+ homeostasis comparably, as reflected by
hypercalcemia and elevated urinary Ca2+ excretion. Hypercalciuria as a consequence of partial
nephrectomy was shown previously [37], and can be explained by increased filtration burden
on remnant glomeruli causing increased ion excretion and parallel development of renal osteo-
dystrophy [38]. The hypercalcemia observed in both models is likely due to early elevated PTH
levels and aggravated by 1,25-dihydroxy vitamin-D3-facilitated intestinal Ca
2+ absorption. In
contrast to our data, hypercalcemia was not observed following ADE treatment in mice [39,
40], although this might be explained by variation in the amount of adenine supplemented to
Fig 5. CKD development altered renal expression of tubular phosphate transporters. (A)mRNA expression of the renal NaPi2a, PIT2 and NaPi2b in
mice with CKD development induced by either 5/6Nx (black bars) or (B) 2 weeks (black bars) and 4 weeks (gray bars) ADE treated mice ADE treatment,
when compared to sham-operated (white bars) or control mice (white bars), respectively. Data are mean ± SEM. *: p<0.05 compared to either sham-
operated or control mice.
doi:10.1371/journal.pone.0142510.g005
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Fig 6. FGF23 administration directly affected renal tubular calcium transport. (A) Intravenous administration of recombinant FGF23 protein (dark-gray
bars) results in increased TRPV5 and a tendency towards elevated calbindin-D28k renal mRNA expression, when compared to vehicle-treated mice (white
bars). Renal EGFPmRNA expression, as a surrogate marker for TRPV5 transcription tended to be increased following FGF23 administration compared to
vehicle-treated mice. (B) Representative immunoblot and (C) semi-quantitative analysis of EGFP (B; upper panel) and β-actin (B; lower panel) protein
expression in renal lysates of vehicle-treated or FGF23 injected mice. Blood (D) Ca2+ and (E) phosphate levels were measured following 24 hrs of FGF23
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the diet, and thus in degree of renal injury induced. While ADE treatment increased blood urea
levels to ~60 mmol/L after 4 weeks in this study, other studies showed maximal urea levels of
around 40 mmol/L, suggesting a distinct degree of renal injury. In agreement with previous
studies [36, 39, 40], ADE treatment dramatically affected Pi homeostasis, a common hallmark
observed in severe CKD [41]. ADE mice presented a significant rise on Pi levels in the blood
despite that elevated fractional excretion was initially adequate to manage Pi loading. In con-
tract, no effects on systemic Pi levels were detected three weeks after 5/6Nx, suggesting that
modest elevated levels of PTH and FGF23 are sufficient to maintain physiological blood Pi
levels.
Third, both experimental models were characterized by a deregulated FGF23-αklotho-vita-
min-D axis. We observed an increase in systemic FGF23 levels and a reduction in renal αklotho
expression. Previously it has been suggested that lack of αklotho might be a driving force for
FGF23 resistance [42–48]. It is, however, not yet clear whether the downregulation of αklotho
can trigger an increase in the expression of FGF23 or vice versa. On the one hand, FGF23
appears to be an early marker of CKD and rises progressively with progression of CKD. On the
other hand, loss of renal αklotho occurs early in CKD, and might be the trigger to increase sys-
temic FGF23 in order to maintain Pi homeostasis. Additionally, rising FGF23 levels upon CKD
might also be due to inflammation [49, 50]. Indeed, it has been shown that both experimental
models significantly induce renal cytokine levels [51, 52] and recent studies point out that ele-
vated blood FGF23 levels are associated with inflammatory components (e.g. cytokines/chemo-
kines) [53–55], and in CKD patients FGF23 and inflammatory markers are often both
increased [55, 56]. Interestingly, a study by Mendoza et al., [57] showed that higher circulatory
levels of FGF23 directly correlate with increased blood levels of several proinflammatory mark-
ers, suggesting that FGF23 is independently associated with inflammation in CKD. In line, we
also observed that two different inflammatory stimuli acutely induce renal FGF23 mRNA
expression. Although, in the current study we did not further elucidate the effects of inflamma-
tory pathways on electrolyte regulatory hormones upon kidney failure, as this was beyond the
scope of the primary project.
Despite elevated blood FGF23, both kidney failure models augmented renal Cyp27b1
expression, probably due to the observed increase in PTH. Comparable data were shown before
in remnant kidneys of nephrectomized rats [58], and following ADE-treatment [59]. In accor-
dance, elevated blood 1,25-dihydroxy vitamin D3 levels were detected following both 5/6Nx
and ADE treatment. Together, these findings indicate that damaged kidneys retain sufficient
vitamin-D synthesizing capacity and that an increased Cyp27b1 expression in the remaining
epithelium might be effective to compensate for the loss of tissue capable of Cyp27b1 expres-
sion due to the reduction in functional kidney mass. Moreover, FGF23-suppressive effects on
1,25-dihydroxy vitamin D3 either directly via modulation of renal Cyp27b1 and Cyp24a1
expression, or indirectly via modulation of PTH synthesis might be hampered due to lower
renal αklotho expression in both kidneys and parathyroid gland, implicating FGF23 resistance
[60–62]. As a proposed pathway, this points towards early high PTH levels as the likely mecha-
nism responsible for amplifying renal vitamin-D synthesis and the consequent rise in blood
1,25-dihydroxy vitamin D3 and Ca
2+ levels. Indeed, both CKD models were characterized by
the development of secondary hyperparathyroidism. Nevertheless, this was not in line with the
observed hypercalcemia, elevated levels of FGF23 and increase in 1,25-dihydroxy vitamin D3,
which all should have suppress PTH level. However, we did not examine parathyroid tissue to
injection. (F)mRNA expression of the renal NaPi2a and NaPi2b in mice injected with FGF23 (gray bars), compared to vehicle-treated mice (white bars). Data
are mean ± SEM. *: p<0.05 compared to control mice.
doi:10.1371/journal.pone.0142510.g006
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study local changes that may drive PTH production or secretion. Development of secondary
hyperparathyroidism could be due to early disturbances on the local calcium sensing receptor,
early decline in parathyroid klotho and possibly lower expression of the vitamin D receptor.
Fourth, to identify local adaptive mechanisms of tubular electrolyte regulation following
CKD, renal expression of crucial Ca2+ and Pi transporters was determined. Gene expression of
Ca2+ transporters TRPV5 and calbindin-D28k was elevated upon CKD. TRPV5 is a crucial
rate-limiting Ca2+ channel expressed in the late distal convoluted and connecting tubule,
responsible for apical Ca2+ influx initiating transcellular reabsorption [63, 64]. Calbindin-D28k
is subsequently responsible for the direct intracellular Ca2+ shuttling towards the basolateral
extrusion side [65]. Together, this suggests that elevated distal tubular Ca2+ reabsorption is
likely the consequence of stimulation by calciotropic factors, including PTH, vitamin D and/or
FGF23 signalling [28, 66, 67]. However, Calbindin-D28k levels were differentially altered in the
ADE dietary intervention model; we observed either reduction or no changes in the Calbindin-
D28k gene expression levels, while it increased in the 5/6Nx model. The reason for that is yet
unclear but it could be that adenine itself might affect the expression/regulation of intracellular
(Ca2+) proteins, that result in a different kinetics compared to TRPV5. In order to determine
whether FGF23 directly affects renal Ca2+ transport, we administered FGF23 to TRPV5-EGFP
transgenic mice to verify its effect on renal EGFP expression, as a surrogate marker for TRPV5
transcription. We found, at most, a tendency towards increased renal EGFP expression. In con-
trast, a previous study indicated a direct effect of FGF23 on renal Ca2+ transport by increasing
TRPV5 gene transcription [68]. A potential explanation for this discrepancy might be that
essential upstream enhancer elements for the transcriptional induction of TRPV5 by FGF23
are lacking in the TRPV5-EGFP mice. Interestingly, WT mice exposed to an inflammatory
stimulus (ConA, but not TNF treatment) demonstrate elevated renal TRPV5 mRNA expres-
sion. Together, these results indicate that both hormonal and inflammatory parameters may
influence renal Ca2+ transport, although the exact stimuli and signalling pathways should be
further investigated in future studies.
In concert with the phosphaturic effects of FGF23 and PTH [69], both kidney failure models
displayed a reduced renal expression of NaPi2a and PIT2, the principal renal type II and III
sodium-dependent Pi transporters, respectively [70–72]. NaPi2a is the main Pi co-transporter
involved in the phosphaturic response to both PTH and FGF23 and it responded to high
FGF23 as expected despite the observed reductions in renal αklotho. On the contrary, renal
NaPi2b was significantly augmented. NaPi2b as a predominant intestinal Pi transporter is also
expressed at the basolateral side of renal epithelial cells. Its expression is increased in response
to active phosphate loading [73]. Hence NaPi2b plays major roles in both the kidney and the
small intestine. Mice with NaPi2b deficiency, exhibited predominantly lower Pi absorption
[74], highlighting a major role of NaPi2b in body Pi homeostasis. As proposed, elevated renal
NaPi2b expression might be an additional mechanism of active tubular Pi secretion, although it
remains unclear whether this also holds true during progressive renal injury to counteract Pi
retention. Since 5/6Nx and ADE treatment induced distinct renal pathophysiological mecha-
nisms, its consequences on renal expression of the sodium-chloride co-transporter (NCC)
were determined. NCC expression was unaffected within both models, suggesting that the
demonstrated effect on the expression kinetics of Ca2+ and Pi transporters within both models
was not simply a reflection of distinct kidney tissue composition compared to sham-operated
or control mice as a potential confounding factor.
Interestingly, the increased blood Ca2+ and active 1,25-dihydroxy vitamin D3 observed in
the current study do not correspond with the classical observation of hypocalcemia due to
reduced 1,25-dihydroxy vitamin D3 levels that are frequently observed in clinically diagnosed
early stage renal disease patients. The reason for this is unclear but it might be related to the
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timing of the measurements performed in our experimental models. This is possibly demon-
strated by the 1,25-dihydroxy vitamin D3 levels observed in the ADE mice model, which is
increased on week 2, and reduced on week 4. Here we present an early renal failure model, pos-
sibly not at steady state yet. Moreover, differences between species may explain why a given
response in animal models differs from patients with CKD [75]. Furthermore, several physio-
logical differences between experimental animal models and patients can be identified, includ-
ing variations in time to develop a certain degree of kidney disease reflecting a particular stage
of CKD. Here, we observed hypercalcemia and hypercalciuria in both experimental CKD mice
models (Table 2) and these observations are supported by previously applied experimental
CKD animal models [76], but not in patients with CKD [77–79]. Human CKD development
reflects a gradual and slow decline of vitamin D levels, contributing to hypocalcemia, whereas
secondary hyperparathyroidism develops over longer time. On the contrary, experimental ani-
mal models are rather short term, due to the methods applied and the shorter lifespan of
rodents [80]. One of the limitations of this study is that we did not keep both models for a lon-
ger period of time. Furthermore, CKD-induced alterations in intestinal and/or bone Ca2+ and
Pi homeostasis might also trigger an increase in blood Ca
2+ and active 1,25-dihydroxy vitamin
D3 observed in these models. Yet, here we primarily focused on renal Ca
2+ and Pi regulatory
mechanisms; hence the existing experiment was not designed to characterize the impact of
CKD-induced alterations on intestinal Ca2+ and Pi transport or bone metabolism. It thus
remains difficult to fully elucidate the compensatory mechanisms occurring following CKD,
which might contribute to the disturbed electrolyte homeostasis observed.
Taken together, our study demonstrated that murine models of partial nephrectomy and
ADE-enriched dietary treatment, both, induce kidney failure that closely resembles CKD devel-
opment, which is associated with disturbed FGF23-αklotho-vitamin-D signalling and a deregu-
lated Ca2+ and Pi homeostasis. Moreover, this study identified local tubular adaptive
mechanisms that are involved in disturbed Ca2+ and Pi regulation, hence enabling new oppor-
tunities to target mineral disturbances emerging as a consequence of CKD development.
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